Literature DB >> 20642965

Diagnostic accuracy of fine needle aspiration cytology in hepatic tumours.

Raja Tariq Nazir1, Muhammad Ashraf Sharif, Muhammad Iqbal, Muhammad Shahbaz Amin.   

Abstract

OBJECTIVE: To determine the diagnostic accuracy of fine-needle aspiration cytology (FNAC) in liver masses to isolate malignant from benign tumours and hepatocellular carcinoma (HCC) from metastatic tumours. STUDY
DESIGN: Cross-sectional, observational. PLACE AND DURATION OF STUDY: Department of Histopathology, Combined Military Hospital, Peshawar, from June 2004 to June 2005.
METHODOLOGY: All the patients with liver masses confirmed by ultrasonography, irrespective of age and gender, were included. Patients with inflammatory lesions were excluded from the study. Selected patients underwent fine-needle aspiration under ultrasound guidance followed by needle biopsy. The cytological slides were stained by haematoxylin and eosin (H & E) stain, while Papanicolaou's stain was employed in selective cases. Needle biopsy fragments were fixed in formalin followed by paraffin embedding and staining with H and E stain. Sensitivity and specificity of FNAC in the diagnosis of liver masses was determined using histological diagnosis on liver biopsy as gold standard.
RESULTS: There were one hundred subjects. The mean age at presentation was 55 + or - 12 years with male to female ratio of 1.7:1. Cytological diagnosis in 19 cases was benign/non-neoplastic and 81 was malignant. Out of the latter, 49 (60.49%) were HCC and 32 (39.51%) were metastatic tumours on cytology. The overall sensitivity, specificity and accuracy of FNAC in the diagnosis of malignant lesions was 95.2%, 100% and 96% respectively using histological diagnosis on liver biopsy as gold standard. Sensitivity of FNAC to differentiate HCC from metastatic tumours in liver was 96% while specificity was 100% having a diagnostic accuracy of 97.5%. The discrepancy in cyto-histological comparison was mainly seen in welldifferentiated and poorly-differentiated HCCs.
CONCLUSION: FNAC of the liver masses is a simple, safe, accurate, economical screening test without significant morbiditythat can be used to identify the vast majority of hepatic neoplasms of primary or metastatic nature with high sensitivity, specificity and diagnostic accuracy.

Entities:  

Mesh:

Year:  2010        PMID: 20642965     DOI: 06.2010/JCPSP.373376

Source DB:  PubMed          Journal:  J Coll Physicians Surg Pak        ISSN: 1022-386X            Impact factor:   0.711


  5 in total

Review 1.  Biomarkers: evaluation of screening for and early diagnosis of hepatocellular carcinoma in Japan and china.

Authors:  Peipei Song; Jianjun Gao; Yoshinori Inagaki; Norihiro Kokudo; Kiyoshi Hasegawa; Yasuhiko Sugawara; Wei Tang
Journal:  Liver Cancer       Date:  2013-01       Impact factor: 11.740

2.  Fusion Image-Guided and Ultrasound-Guided Fine Needle Aspiration in Patients With Suspected Hepatic Metastases.

Authors:  Lawrence Aj; Naveen Kalra; Anmol Bhatia; Radhika Srinivasan; Ajay Gulati; Rakesh Kapoor; Vikas Gupta; Radha K Dhiman; Yogesh Chawla; Niranjan Khandelwal
Journal:  J Clin Exp Hepatol       Date:  2019-01-25

3.  HURP expression-assisted risk scores identify prognosis distinguishable subgroups in early stage liver cancer.

Authors:  Ming-Ling Chang; Shi-Ming Lin; Chau-Ting Yeh
Journal:  PLoS One       Date:  2011-10-17       Impact factor: 3.240

4.  Imaging Accuracy in Diagnosis of Different Focal Liver Lesions: A Retrospective Study in North of Iran.

Authors:  Ahmad Alizadeh; Fariborz Mansour-Ghanaei; Faezeh Berengi Bagheri; Hossein Froutan; Yaser Froutan; Farahnaz Joukar; Zahra Atrkar-Roushan; Seyed Ali Chavoshi; Soheil Hassanipour
Journal:  J Gastrointest Cancer       Date:  2021-09

5.  Epidemiology, clinical features, and impact of food habits on the risk of hepatocellular carcinoma: A case-control study in Bangladesh.

Authors:  M Al-Amin Shawon; M Abul Khair Yousuf; Enayetur Raheem; Sium Ahmed; Tyeaba Tasnim Dipti; Mohammad Razuanul Hoque; Hiroaki Taniguchi; M Rezaul Karim
Journal:  PLoS One       Date:  2020-04-27       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.